Hand in hand: public endorsement of climate change mitigation and adaptation

This research investigated how an individual’s endorsements of mitigation and adaptation relate to each other, and how well each of these can be accounted for by relevant social psychological factors. Based on survey data from two European convenience samples (N = 616 / 309) we found that public endorsements of mitigation and adaptation are strongly associated: Someone who is willing to reduce greenhouse gas emissions (mitigation) is also willing to prepare for climate change impacts (adaptation). Moreover, people endorsed the two response strategies for similar reasons: People who believe that climate change is real and dangerous, who have positive attitudes about protecting the environment and the climate, and who perceive climate change as a risk, are willing to respond to climate change. Furthermore, distinguishing between (spatially) proximal and distant risk perceptions suggested that the idea of portraying climate change as a proximal (i.e., local) threat might indeed be effective in promoting personal actions. However, to gain endorsement of broader societal initiatives such as policy support, it seems advisable to turn to the distant risks of climate change. The notion that “localising” climate change might not be the panacea for engaging people in this domain is discussed in regard to previous theory and research.

Surgical Treatment of Traumatic Myositis Ossificans of the Extensor Carpi Radialis Muscle in a Dog

OBJECTIVES To report clinical signs, diagnostic imaging findings, and outcome in a dog with traumatic myositis ossificans of the origin of the extensor carpi radialis muscle. STUDY DESIGN Clinical report. ANIMALS An 8-month-old intact female Irish Setter Dog. METHODS After radiographic and computed tomographic evaluation of an osseous proliferation arising from the cranial cortex of the right distal humeral diaphysis, the protruding bone was surgically removed and evaluated by histopathology. RESULTS Traumatic myositis ossificans was successfully treated with surgical removal of the osseous proliferation resulting in improved postoperative range of motion of the right elbow joint. There was no evidence of lameness or abnormal bone regrowth associated with the surgical site radiographically at follow up. CONCLUSION Surgical removal of a traumatic myositis ossificans lesion resulted in full return to function in a young, competitive show dog.

The future of transcatheter mitral valve interventions: competitive or complementary role of repair vs. replacement?

Transcatheter mitral interventions has been developed to address an unmet clinical need and may be an alternative therapeutic option to surgery with the intent to provide symptomatic and prognostic benefit. Beyond MitraClip therapy, alternative repair technologies are being developed to expand the transcatheter intervention armamentarium. Recently, the feasibility of transcatheter mitral valve implantation in native non-calcified valves has been reported in very high-risk patients. Acknowledging the lack of scientific evidence to date, it is difficult to predict what the ultimate future role of transcatheter mitral valve interventions will be. The purpose of the present report is to review the current state-of-the-art of mitral valve intervention, and to identify the potential future scenarios, which might benefit most from the transcatheter repair and replacement devices under development.

Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.

BACKGROUND Drug eluting stents with durable polymers may be associated with hypersensitivity, delayed healing, and incomplete endothelialization, which may contribute to late/very late stent thrombosis and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. The SYNERGY stent is a thin-strut, platinum chromium metal alloy platform with an ultrathin bioabsorbable Poly(D,L-lactide-co-glycolide) abluminal everolimus-eluting polymer. We performed a multicenter, randomized controlled trial for regulatory approval to determine noninferiority of the SYNERGY stent to the durable polymer PROMUS Element Plus everolimus-eluting stent. METHODS AND RESULTS Patients (n=1684) scheduled to undergo percutaneous coronary intervention for non-ST-segment-elevation acute coronary syndrome or stable coronary artery disease were randomized to receive either the SYNERGY stent or the PROMUS Element Plus stent. The primary end point of 12-month target lesion failure was observed in 6.7% of SYNERGY and 6.5% PROMUS Element Plus treated subjects by intention-to-treat (P=0.83 for difference; P=0.0005 for noninferiority), and 6.4% in both the groups by per-protocol analysis (P=0.0003 for noninferiority). Clinically indicated revascularization of the target lesion or definite/probable stent thrombosis were observed in 2.6% versus 1.7% (P=0.21) and 0.4% versus 0.6% (P=0.50) of SYNERGY versus PROMUS Element Plus-treated subjects, respectively. CONCLUSIONS In this randomized trial, the SYNERGY bioabsorbable polymer everolimus-eluting stent was noninferior to the PROMUS Element Plus everolimus-eluting stent with respect to 1-year target lesion failure. These data support the relative safety and efficacy of SYNERGY in a broad range of patients undergoing percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01665053.

European Dermatology Forum Guidelines on topical photodynamic therapy

Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, squamous cell carcinoma in-situ, superficial and certain thin basal cell carcinomas. Recurrence rates are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma. PDT can be used both as a lesional or as a field therapy and has the potential to delay/reduce the development of new lesions. PDT has also been studied for its place in the treatment of, as well as its potential to prevent, superficial skin cancers in immune-suppressed patients, although sustained clearance rates are lower than for immunocompetent individuals. Many additional indications have been evaluated, including photo-rejuvenation and inflammatory and infective dermatoses. This S2 guideline considers all current and emerging indications for the use of topical photodynamic therapy in Dermatology, prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence. An unabridged version of this guideline is available online at: http://www.euroderm.org/edf/index.php/edf-guidelines.

Practical approach to the use of daylight photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: a European consensus

INTRODUCTION Daylight-mediated photodynamic therapy has been shown to be an effective therapy for actinic keratoses (AKs) and a simple and tolerable treatment procedure in three randomized Scandinavian studies and two recent Phase III randomized controlled studies in Australia and Europe. OBJECTIVES To establish consensus recommendations for the use of daylight photodynamic therapy (DL-PDT) using topical methyl aminolaevulinate (MAL) in European patients with AKs. METHODS The DL-PDT consensus recommendations were developed on behalf of the European Society for Photodynamic Therapy in Dermatology and comprised of 10 dermatologists from different European countries with experience in how to treat AK patients with PDT. Consensus was developed based on literature review and experience of the experts in the treatment of AK using DL-PDT. RESULTS The recommendations arising from this panel of experts provide general guidance on the use of DL-PDT as a dermatological procedure with specific guidance regarding patient selection, therapeutic indications, when to treat, pre-treatment skin preparation, MAL application and daylight exposure for patients with AK in different countries of Europe. CONCLUSIONS This consensus recommendation provides a framework for physicians to perform DL-PDT with MAL cream while ensuring efficiency and safety in the treatment of patients with AK in different European countries.

Galactofuranose in Mycoplasma mycoides is important for membrane integrity and conceals adhesins but does not contribute to serum resistance.

Mycoplasma mycoides subsp. capri (Mmc) and subsp. mycoides (Mmm) are important ruminant pathogens worldwide causing diseases such as pleuropneumonia, mastitis and septicaemia. They express galactofuranose residues on their surface, but their role in pathogenesis has not yet been determined. The M. mycoides genomes contain up to several copies of the glf gene, which encodes an enzyme catalysing the last step in the synthesis of galactofuranose. We generated a deletion of the glf gene in a strain of Mmc using genome transplantation and tandem repeat endonuclease coupled cleavage (TREC) with yeast as an intermediary host for the genome editing. As expected, the resulting YCp1.1-Δglf strain did not produce the galactofuranose-containing glycans as shown by immunoblots and immuno-electronmicroscopy employing a galactofuranose specific monoclonal antibody. The mutant lacking galactofuranose exhibited a decreased growth rate and a significantly enhanced adhesion to small ruminant cells. The mutant was also 'leaking' as revealed by a β-galactosidase-based assay employing a membrane impermeable substrate. These findings indicate that galactofuranose-containing polysaccharides conceal adhesins and are important for membrane integrity. Unexpectedly, the mutant strain showed increased serum resistance.

Annual Report Central Administrative Services 2006/2007

University of Connecticut Health Center, Central Administrative Services, Annual Report, Fiscal Year 2006-2007; Submitted by Barry Feldman, Vice President & Chief Operation Officer, University of Connecticut, and Susan Whetstone, Chief Administrative Officer, UConn Health Center, August 2007

Na 1 Nachlass Max Horkheimer, 37 - Korrespondenzen u.a. mit Dorthy I. Mulgrave (p. I 18, 335-517)

1 Brief von Margot von Mendelssohn an Max Horkheimer, 20.05.1948; 6 Briefe zwsichen Charles E. Merriam und Max Horkheimer, 1940-1941; 4 Briefe zwischen Josef Messinger und Max Horkheimer, 1940; 1 Curriculum Vitae von Alfred Meusel an Max Horkheimer; 1 Brief von Max Horkheimer an Gerhard Meyer, 17.10.1938; 3 Briefe zwischen Hans A. Meyer und Max Horkheimer´09.10.1939, 1947; 2 Briefe zwischen Julie Meyer und Max Horkheimer, 12.04.1941, 15.04.1941; 43 Briefe zwischen Hermann Meyer-Lindenberg, Oscar Meyer und Max Horkheimer sowie Briefwechsel mit Hadley Cantril; 2 Briefe zwischen Hadley Cantril und Theodor W. Adorno, 22.05.1941, 28.05.1941; 1 Brief von Jerome Michael an Margot von Mendelssohn, 10.01.1941; 2 Briefe und 2 Beilagen zwischen Joseph Mire und Max Horkheimer, 16.03.1941, 28.03.1941; 6 Briefe zwischen Mitchell, Silberberg & Knupp, Los Angeles und Max Horkheimer, 1942, 1943; 1 Brief von Friedrich Pollock an Wesley C. Mitchell, 06.08.1940; 3 Briefe zwischen Hans Mohr und Max Horkheimer, 29.03.1946, 1946; 1 Brief von Herbert Moeller Morton an Max Horkheimer, 25.02.1940; 1 Brief von Max Horkheimer an den Chairman of the Committee on General Scholarships, Cambridge Massachusetts, 01.03.1940; 2 Briefe von David H. Moses an Max Horkheimer, 1939; 1 Brief von Franz Neumann an Philip Mosley, 28.04.1941; 49 Briefe zwischen Dorthy I. Mulgrave und Max Horkheimer, 1936-1940; 1 Brief von Max Horkheimer an das Municipal Court, San Francisco, 24.12.1948;

Emin Pascha und die Meuterei in Äquatoria : neunmonatlicher Aufenthalt und Gefangenschaft in den letzten der Sudan-Provinzen

von A. J. Mounteney Jephson und Henry M. Stanley

Henry M. Stanleys Reise durch den dunklen Weltteil : nach Stanleys Berichten für weitere Kreise

Henry M. Stanley. Bearb. von Berthold Volz

Stanley's Briefe über Emin Pascha's Befreiung

Henry M. Stanley. Hrsg. von J. Scott Keltie

Na 1 Nachlass Max Horkheimer, 559 - Korrespondenzen mit Leo Löwenthal (p. VI 25, 1-248)

124 Briefe zwischen Leo Löwenthal und Max Horkheimer; 1 Brief von Leo Löwenthal an Theodor W. Adorno, 29.12.1954; 2 Briefe zwischen Max Horkheimer und Marjorie Fiske, 1954/1955; 2 Briefe zwischen Leo Löwenthal und Frederick Ungar, Oktober 1954; 2 Briefe zwischen Daniel Lerner und Leo Löwenthal, Oktober 1954; 3 Briefe zwischen Leo Löwenthal und Herbert Blumer, Oktober 1954; 1 Brief von Alice H. Maier an H. P. Edelman, 10.06.1954; 2 Briefe von Leo Löwenthal an The Trustes of Hermann Weil Memorial Foundation (New York), 27.04.1955; 1 Brief von Max Horkheimer an The Trustes of Hermann Weil Memorial Foundation (New York), Juni 1954; 4 Briefe zwischen Leo Löwenthal und Chauncy D. Harris, 1954/1955; 2 Briefe zwischen John I. Kirkpatrick und Leo Löwenthal, 1954; 3 Briefe zwischen Leo Löwenthal und R. Wendell Harrison, Mai 1954; 2 Briefe von Leo Löwenthal an Gustave E. von Grunebaum, 1954; 1 Brief von Leo Löwenthal an Morton Grodzins, 12.05.1954; 2 Briefe von Max Horkheimer an Charles Y. Glock, 1954; 1 Brief von Jeremiah Kaplan an Leo Löwenthal, 15.03.1954; 2 Briefe zwischen Leo Löwenthal und Max Rheinstein, März 1954; 1 Brief von Frederick Pollock an Max Rheinstein, [1954];